Heart valve replacement- thromboembolic disorder, Prophylaxis.

Dipyridamole's mechanisms of action may involve its ability to increase endogenous concentrations of adenosine, which is a coronary vasodilator and a platelet aggregation inhibitor, and of cyclic adenosine monophosphate (cAMP), which decreases platelet activation.

Systemic: Slowly absorbed; Bioavailability: 27 to 66%; Metabolism- Hepatic: Metabolite: glucuronic acid conjugate; Excretion: Biliary; Elimination Half Life: 10 h

Hypersensitivity to dipyridamole; acute myocardial infarction.

B [FDA.AUS]

Infant risk cannot be ruled out. [MDX]

Adverse effects reported including headache, dizziness, abdominal discomfort, skin rash.

Thromboembolic disorder, Prophylaxis: 75-100 mg PO QID as an adjunct to warfarin therapy